IP Library Granted Patent US 9,304,126
Granted Patent B2
US 9,304,126 · App. 13/970,667 · Granted Apr 5, 2016

Haptens of quetiapine

Inventors: Matthew Garrett Donahue (Warrington, PA); Yong Gong (Warrington, PA); Rhys Salter (Doylestown, PA); Eric Hryhorenko (Hilton, NY); Thomas R. DeCory (Pittsford, NY); Bart Remmerie (Ghent, BE); Banumathi Sankaran (Pittsford, NY)
Assignees: Janssen Pharmaceutica NV; Ortho-Clinical Diagnostics, Inc.
G01N33/5308A61K47/4833A61K47/48246A61K47/48284C07D281/16C07D417/12C07D417/14G01N2500/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,304,126
App. No.
13/970,667
Granted
Apr 5, 2016
Kind
B2
Abstract

The invention relates to compounds of Formula I, wherein R 1 , R 2 , and R 3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from quetiapine. The invention also relates to conjugates of a quetiapine hapten and a protein.

Claims (68)

1. The compound of Formula I

wherein:

R 1 is H,

CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 2 is H,

CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 3 is H; provided that either R 1 or R 2 must be H, and further provided that both R 1 and R 2 may not be H simultaneously;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

2. The compound of claim 1

wherein:

R 1 is

CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 2 is H;

R 3 is H;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

3. The compound of claim 1

wherein:

R 1 is H;

R 2 is

CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 3 is H;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

4. The compound of claim 1

wherein:

R 1 is H,

CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 2 is H,

CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H; provided that either R 1 or R 2 must be H, and further provided that both R 1 and R 2 may not be H simultaneously;

R 3 is H;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

5. The compound of claim 1

wherein:

R 1 is H,

or CH 2 NH 2 ;

R 2 is H,

or CH 2 NH 2 ; provided that either R 1 or R 2 must be H, and further provided that both R 1 and R 2 may not be H simultaneously;

R 3 is H;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

6. The compound of claim 1 , selected from the group consisting of:

7. A conjugate of a compound of claim 1 and a protein, wherein said protein is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

8. A conjugate of the compound of claim 2 and a protein, wherein said protein is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

9. A conjugate of the compound of claim 3 and a protein, wherein said protein is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

10. A conjugate of the compound of claim 4 and a protein, wherein said protein is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

11. A conjugate of the compound of claim 5 and a protein, wherein said protein is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

12. The conjugate of claim 7 wherein the compound is

13. A product made by the process of contacting a compound of claim 1 with a protein, wherein said protein is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

14. A product made by the process of contacting a compound of claim 2 with a protein, wherein said protein is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

15. A product made by the process of contacting a compound of claim 3 with a protein, wherein said protein is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

16. A product made by the process of contacting a compound of claim 4 with a protein, wherein said protein is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

17. A product made by the process of contacting a compound of claim 5 with a protein, wherein said protein is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

18. A product made by the process of contacting a compound which is

with a protein, wherein said protein is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

19. The compound of claim 1

wherein:

R 1 is H,

CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 2 is H,

CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) m CO 2 H;

R 3 is H; provided that either R 1 or R 2 must be H, and further provided that both R 1 and R 2 may not be H simultaneously;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

20. A conjugate of a compound of claim 19 and a protein, wherein said protein is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

21. A product made by the process of contacting a compound of claim 19 with a protein, wherein said protein is selected from keyhole limpet hemocyanin, ovalbumin or bovine thyroglobulin.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2016
From: ORTHO-CLINICAL DIAGNOSTICS, INC.
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 039615/0175 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2014
From: HRYHORENKO, ERIC; DECORY, THOMAS R.; SANKARAN, BANUMATHI
To: ORTHO-CLINICAL DIAGNOSTICS, INC.
Reel/Frame 033669/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2014
From: REMMERIE, BART
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 033669/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2014
From: GONG, YONG; SALTER, RHYS
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 033669/0988 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2014
From: DONAHUE, MATTHEW GARRETT
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 033670/0025 →
Continuity (2)
Provisional Application 61691462 · Aug 21, 2012
Related Publication 20140221616A1 · Aug 7, 2014